NAS:SNGX (USA) Also trade in: Germany

Soligenix Inc

$ 1.14 -0.03 (-2.56%)
Volume: 257,302 Avg Vol (1m): 117,526
Market Cap $: 21.04 Mil Enterprise Value $: 13.84 Mil
P/E (TTM): 0.00 P/B: 3.93
Earnings Power Value -4.9
Net Current Asset Value 0.27
Tangible Book 0.29
Projected FCF -2.63
Median P/S Value 1.52
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6.4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt range over the past 10 years
Min: 0.57, Med: 10000, Max: 10000
Current: 10000
0.57
10000
Equity-to-Asset 0.56
Equity-to-Asset range over the past 10 years
Min: -0.79, Med: 0.66, Max: 0.97
Current: 0.56
-0.79
0.97
Interest Coverage No Debt
N/A
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -24.68
DISTRESS
GREY
SAFE
Beneish M-Score -1.08
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 12.33%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -170.21
Operating Margin range over the past 10 years
Min: -404.41, Med: -144.48, Max: -38.63
Current: -170.21
-404.41
-38.63
Net Margin % -154.98
Net Margin range over the past 10 years
Min: -379.21, Med: -131.97, Max: -31.05
Current: -154.98
-379.21
-31.05
ROE % -148.29
ROE range over the past 10 years
Min: -1129.59, Med: -99.67, Max: -33.63
Current: -148.29
-1129.59
-33.63
ROA % -86.96
ROA range over the past 10 years
Min: -155.11, Med: -83.67, Max: -27.2
Current: -86.96
-155.11
-27.2
ROC (Joel Greenblatt) % -35295.28
ROC (Joel Greenblatt) range over the past 10 years
Min: -38686.49, Med: -26227.53, Max: -14363.64
Current: -35295.28
-38686.49
-14363.64
3-Year Total Revenue Growth Rate -15.80
N/A
3-Year Total EBITDA Growth Rate -9.50
3-Year EBITDA Growth Rate range over the past 10 years
Min: -30.9, Med: 19.8, Max: 49.6
Current: 36.2
-30.9
49.6
3-Year EPS w/o NRI Growth Rate 39.00
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -52.8, Med: 24.85, Max: 48.9
Current: 39
-52.8
48.9

» SNGX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:SNGX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:TROV NAS:NVUS XSAT:QUIA MIC:LIFE OSTO:CYXO NAS:DFFN LSE:HEMO XCNQ:PREV ASX:1AD ASX:IMC ASX:RGS AMEX:IBIO OSTO:A1M ASX:BNO XSAT:SYNACT OTCPK:GTBP OSL:SOFTOX-ME OTCPK:BSTG OTCPK:FNAM NAS:DARE
Traded in other countries DOA2.Germany
Address 29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics business segment is developing a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma whereas the Vaccines/BioDefense business segment includes development programs for RiVax, a ricin toxin vaccine candidate; OrbeShield, a GI acute radiation syndrome therapeutic candidate; and SGX943, a melioidosis therapeutic candidate.

Ratios

Current vs industry vs history
PB Ratio 3.93
PB Ratio range over the past 10 years
Min: 0.55, Med: 4.18, Max: 800
Current: 3.93
0.55
800
PS Ratio 2.88
PS Ratio range over the past 10 years
Min: 0.32, Med: 3.85, Max: 28.56
Current: 2.88
0.32
28.56
EV-to-EBIT -1.52
EV-to-EBIT range over the past 10 years
Min: -14.9, Med: -2.9, Max: 1.1
Current: -1.52
-14.9
1.1
EV-to-EBITDA -1.52
EV-to-EBITDA range over the past 10 years
Min: -15.8, Med: -3, Max: 1.3
Current: -1.52
-15.8
1.3
EV-to-Revenue 2.63
EV-to-Revenue range over the past 10 years
Min: -0.2, Med: 3.5, Max: 27
Current: 2.63
-0.2
27
Current Ratio 2.20
Current Ratio range over the past 10 years
Min: 0.12, Med: 3.08, Max: 33.8
Current: 2.2
0.12
33.8
Quick Ratio 2.20
Quick Ratio range over the past 10 years
Min: 0.12, Med: 3.08, Max: 33.8
Current: 2.2
0.12
33.8
Days Sales Outstanding 76.58
Days Sales Outstanding range over the past 10 years
Min: 3.11, Med: 40.75, Max: 98.16
Current: 76.58
3.11
98.16
Days Payable 127.07
Days Payable range over the past 10 years
Min: 73.92, Med: 187.55, Max: 373.02
Current: 127.07
73.92
373.02

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -61.50
3-Year Share Buyback Rate range over the past 10 years
Min: -61.5, Med: -31.15, Max: -6.3
Current: -61.5
-61.5
-6.3

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.93
Price-to-Tangible-Book range over the past 10 years
Min: 0.84, Med: 5.87, Max: 36.75
Current: 3.93
0.84
36.75
Price-to-Median-PS-Value 0.75
Price-to-Median-PS-Value range over the past 10 years
Min: 0.1, Med: 1.53, Max: 318.35
Current: 0.75
0.1
318.35
Earnings Yield (Joel Greenblatt) % -64.64
Earnings Yield (Greenblatt) range over the past 10 years
Min: -10164.7, Med: -31.6, Max: 9169.7
Current: -64.64
-10164.7
9169.7

More Statistics

Revenue (TTM) (Mil) $ 5.27
EPS (TTM) $ -0.56
Beta 1.6
Volatility % 70.38
52-Week Range $ 0.65 - 2.2
Shares Outstanding (Mil) 18.45

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y